AG˹ٷ

STOCK TITAN

CNO Financial Group Reports Second Quarter 2025 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

CNO Financial Group (NYSE:CNO) reported second quarter 2025 net income of $91.8 million ($0.91 per diluted share), compared to $116.3 million ($1.06 per diluted share) in 2Q24. Net operating income was $87.5 million ($0.87 per diluted share), down from $114.6 million ($1.05 per diluted share) in 2Q24.

Key operational highlights include: 17% increase in total new annualized premiums, 22% growth in Life NAP, 11% growth in Health NAP, and 19% increase in annuity collected premiums. The company returned $116.7 million to shareholders and maintained a strong statutory risk-based capital ratio of 378%.

Book value per share reached $25.92, while book value per diluted share excluding accumulated other comprehensive loss was $38.05, up 6%. The company achieved an operating ROE of 11.8% and remains on track to meet its 2025-2027 return on equity targets.

CNO Financial Group (NYSE:CNO) ha riportato un utile netto del secondo trimestre 2025 pari a 91,8 milioni di dollari (0,91 dollari per azione diluita), rispetto a 116,3 milioni di dollari (1,06 dollari per azione diluita) nel 2° trimestre 2024. L’utile operativo netto è stato di 87,5 milioni di dollari (0,87 dollari per azione diluita), in calo rispetto a 114,6 milioni di dollari (1,05 dollari per azione diluita) nel 2° trimestre 2024.

I principali dati operativi includono: un aumento del 17% dei premi annualizzati totali, una crescita del 22% dei premi annualizzati Vita, un incremento dell�11% dei premi annualizzati Salute e un aumento del 19% dei premi raccolti sulle rendite. L’azienda ha restituito 116,7 milioni di dollari agli azionisti e ha mantenuto un solido indice di capitale basato sul rischio statutario del 378%.

Il valore contabile per azione ha raggiunto 25,92 dollari, mentre il valore contabile per azione diluita, escludendo le perdite complessive accumulate, è stato di 38,05 dollari, con un aumento del 6%. L’azienda ha ottenuto un ROE operativo dell�11,8% e resta in linea per raggiungere gli obiettivi di rendimento del capitale proprio per il periodo 2025-2027.

CNO Financial Group (NYSE:CNO) reportó un ingreso neto en el segundo trimestre de 2025 de 91,8 millones de dólares (0,91 dólares por acción diluida), en comparación con 116,3 millones de dólares (1,06 dólares por acción diluida) en el 2T24. El ingreso operativo neto fue de 87,5 millones de dólares (0,87 dólares por acción diluida), descendiendo desde 114,6 millones de dólares (1,05 dólares por acción diluida) en el 2T24.

Los aspectos operativos clave incluyen: un aumento del 17% en primas anuales nuevas totales, un crecimiento del 22% en primas anuales nuevas de Vida, un incremento del 11% en primas anuales nuevas de Salud y un aumento del 19% en primas cobradas de anualidades. La compañía devolvió 116,7 millones de dólares a los accionistas y mantuvo una sólida ratio de capital basado en riesgo estatutario del 378%.

El valor contable por acción alcanzó 25,92 dólares, mientras que el valor contable por acción diluida, excluyendo pérdidas acumuladas por otros conceptos integrales, fue de 38,05 dólares, un aumento del 6%. La empresa logró un ROE operativo del 11,8% y sigue en camino de cumplir sus objetivos de retorno sobre el capital para 2025-2027.

CNO Financial Group (NYSE:CNO)� 2025� 2분기 순이익으� 9,180� 달러 (희석 주당 0.91달러)� 보고했으�, 이는 2024� 2분기� 1� 1,630� 달러 (희석 주당 1.06달러)와 비교됩니�. 순영업이익은 8,750� 달러 (희석 주당 0.87달러)� 2024� 2분기� 1� 1,460� 달러 (희석 주당 1.05달러)에서 감소했습니다.

주요 운영 성과로는 � 신규 연간� 보험� 17% 증가, 생명보험 신규 연간� 보험� 22% 성장, 건강보험 신규 연간� 보험� 11% 성장, 연금 수령 보험� 19% 증가가 포함됩니�. 회사� 1� 1,670� 달러� 주주들에� 환원했으�, 378%� 견고� 법정 위험기반 자본 비율� 유지했습니다.

주당 장부 가치는 25.92달러� 도달했으�, 누적 기타 포괄손실� 제외� 희석 주당 장부 가치는 38.05달러� 6% 상승했습니다. 회사� 11.8%� 영업 자기자본이익�(ROE)� 달성했으� 2025-2027� 자기자본이익� 목표 달성� 위한 순항 중입니다.

CNO Financial Group (NYSE:CNO) a annoncé un bénéfice net au deuxième trimestre 2025 de 91,8 millions de dollars (0,91 dollar par action diluée), contre 116,3 millions de dollars (1,06 dollar par action diluée) au 2T24. Le revenu net d’exploitation s’est élevé à 87,5 millions de dollars (0,87 dollar par action diluée), en baisse par rapport à 114,6 millions de dollars (1,05 dollar par action diluée) au 2T24.

Les faits saillants opérationnels clés incluent : une augmentation de 17 % des primes annuelles nouvelles totales, une croissance de 22 % des primes annuelles nouvelles Vie, une croissance de 11 % des primes annuelles nouvelles Santé, et une hausse de 19 % des primes collectées sur les rentes. La société a reversé 116,7 millions de dollars aux actionnaires et a maintenu un solide ratio de capital réglementaire basé sur le risque de 378 %.

La valeur comptable par action a atteint 25,92 dollars, tandis que la valeur comptable par action diluée hors pertes globales autres cumulées s’est élevée à 38,05 dollars, en hausse de 6 %. La société a réalisé un ROE opérationnel de 11,8 % et reste en bonne voie pour atteindre ses objectifs de rendement des capitaux propres pour la période 2025-2027.

CNO Financial Group (NYSE:CNO) meldete für das zweite Quartal 2025 einen Nettogewinn von 91,8 Millionen US-Dollar (0,91 US-Dollar je verwässerter Aktie), verglichen mit 116,3 Millionen US-Dollar (1,06 US-Dollar je verwässerter Aktie) im 2. Quartal 2024. Der operative Nettogewinn betrug 87,5 Millionen US-Dollar (0,87 US-Dollar je verwässerter Aktie), gegenüber 114,6 Millionen US-Dollar (1,05 US-Dollar je verwässerter Aktie) im 2. Quartal 2024.

Wesentliche operative Highlights umfassen: ein 17%iger Anstieg der gesamten neuen annualisierten Prämien, 22% Wachstum bei Life NAP, 11% Wachstum bei Health NAP und 19% Zuwachs bei den eingezogenen Rentenprämien. Das Unternehmen gab 116,7 Millionen US-Dollar an die Aktionäre zurück und hielt eine starke aufsichtsrechtliche risikobasierte Kapitalquote von 378% aufrecht.

Der Buchwert je Aktie erreichte 25,92 US-Dollar, während der Buchwert je verwässerter Aktie ohne kumulierte sonstige umfassende Verluste bei 38,05 US-Dollar lag, ein Anstieg um 6%. Das Unternehmen erzielte eine operative Eigenkapitalrendite (ROE) von 11,8% und ist auf Kurs, seine Eigenkapitalrenditeziele für 2025�2027 zu erreichen.

Positive
  • Total new annualized premiums up 17% year-over-year
  • Strong growth across segments with Life NAP up 22% and Health NAP up 11%
  • Annuity collected premiums increased 19%
  • Client assets in brokerage and advisory up 27%
  • Returned $116.7 million to shareholders
  • Maintained robust capital position with 378% risk-based capital ratio
  • Operating ROE of 11.8%, showing sustained profitability
Negative
  • Net income decreased 21% year-over-year to $91.8 million
  • Net operating income declined 24% to $87.5 million
  • Investment income not allocated to product lines down 25%
  • Net investment losses of $21.8 million in Q2 2025

Insights

CNO posted mixed Q2 results with 17% premium growth but 17% YoY EPS decline; maintains healthy 11.2% operating ROE.

CNO Financial delivered solid premium growth in Q2 2025, with total new annualized premiums increasing 17% year-over-year. The growth was broad-based across business lines, with Life NAP up 22%, Health NAP up 11%, and annuity collected premiums rising 19%. Both major divisions showed strong performance with Consumer up 17% and Worksite up 16%.

However, profitability metrics showed some pressure compared to the previous year. Net operating income declined to $87.5 million ($0.87 per diluted share) from $114.6 million ($1.05 per diluted share) in Q2 2024, representing a 17% decrease in EPS. Management attributes this decline to an elevated earnings base in Q2 2024 rather than fundamental weakness, noting that year-to-date EPS is up 6%.

The company's investment portfolio faced some challenges with $21.8 million in net investment losses in Q2, including a $1.0 million unfavorable change in credit loss allowance. However, book value per diluted share excluding AOCI increased 6% year-over-year to $38.05.

Capital management remains a priority with $116.7 million returned to shareholders in Q2, including $100 million in share repurchases at an average cost of $38.09 per share and $16.7 million in dividends. The company's leverage improved significantly with debt-to-total capital excluding AOCI decreasing to 26.1% from 32.1% at year-end 2024.

Most importantly, CNO's operating ROE excluding significant items reached 11.2% for the trailing four quarters, up from 10.0% in the prior year period, indicating the company is successfully executing on its profitability targets despite quarterly earnings volatility.

Strong production; Solid financial results; On track to deliver 2025-2027 ROE targets

CARMEL, Ind., July 28, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE: CNO) today reported net income of $91.8 million, or $0.91 per diluted share, in 2Q25 compared to $116.3 million or $1.06 per diluted share, in 2Q24. Non-economic accounting impacts due to market volatility increased net income in both 2Q25 and 2Q24. Net operating income,(1) which excludes these non-economic accounting impacts, was $87.5 million, or $0.87 per diluted share, in 2Q25 compared to $114.6 million, or $1.05 per diluted share, in 2Q24.

"Building on our strong second quarter and first half results, CNO remains on track to achieve our full-year 2025-2027 return on equity targets," said Gary C. Bhojwani, chief executive officer. "Our consistent, repeatable results demonstrate the steady execution of our strategic plan and continue to position us for sustained, profitable growth."

"Our business fundamentals remain strong. This quarter marked our twelfth consecutive quarter of sustained sales momentum underpinned by growing underwriting margins and investment income. Second quarter 2024 earnings were elevated relative to our typical run rate, thereby impacting 2025 comparables. Operating earnings per share are up 6% year-to-date, in line with expectations. Our robust capital position enabled us to once again deliver meaningful results while returning capital to shareholders and investing in the long-term health of the business."

"CNO remains uniquely positioned to serve the growing needs of the middle-income market with our diverse products and distribution. With considerable momentum and favorable demographic tailwinds, we are well-equipped to navigate the evolving economic environment and continue to drive improved profitability."

Second Quarter 2025 Highlights (as compared to the corresponding period in the prior year unless otherwise stated)

  • Total new annualized premiums ("NAP")(4) up 17%; Total Life NAP up 22%; Total Health NAP up 11%
  • Consumer Division NAP up 17%; Worksite Division NAP up 16%
  • Annuity collected premiums up 19%; Client assets in brokerage and advisory up 27%
  • Returned $116.7 million to shareholders
  • Book value per share was $25.92; Book value per diluted share, excluding accumulated other comprehensive loss,(2) was $38.05, up 6%
  • Return on equity ("ROE") of 11.9%; Operating ROE(5) of 11.8%

FINANCIAL SUMMARY
Quarter End
(Amounts in millions, except per share data)
(Unaudited)

Net operating income, a non-GAAP(a) financial measure, is used consistently by CNO's management to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry. It differs from net income primarily because it excludes certain non-operating items as defined in note (1). Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company's business. Net income is the most directly comparable GAAP measure.


Per diluted share









Quarter ended


Quarter ended


June 30,


June 30,


2025



2024


%
change


2025



2024


%
change















Income from insurance products (b)

1.03



$ 1.10


(6)


$ 103.0



$ 120.5


(15)

Fee income

0.01



0.01



0.8



0.8


Investment income not allocated to product lines (c)

0.33



0.41


(20)


33.8



44.8


(25)

Expenses not allocated to product lines

(0.25)



(0.16)


56


(25.3)



(17.5)


45

Operating earnings before taxes

1.12



1.36




112.3



148.6



Income tax expense on operating income

(0.25)



(0.31)


(19)


(24.8)



(34.0)


(27)

Net operating income (1)

0.87



1.05


(17)


87.5



114.6


(24)

Net realized investment losses from sales,
impairments and change in allowance for credit
losses

(0.22)



(0.20)




(21.8)



(21.9)



Net change in market value of investments
recognized in earnings

0.03



0.04




3.4



4.7



Changes in fair value of embedded derivative
liabilities and market risk benefits

0.25



0.15




25.2



16.8



Other

(0.01)



0.02




(1.1)



2.4



Non-operating income before taxes

0.05



0.01




5.7



2.0



Income tax expense on non-operating income

(0.01)






(1.4)



(0.3)



Net non-operating income

0.04



0.01




4.3



1.7



Net income

$ 0.91



$ 1.06




$ 91.8



$ 116.3

















Weighted average diluted shares outstanding

100.4



109.3










____________________

(a)

GAAP is defined as accounting principles generally accepted in the United States of America.

(b)

Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Insurance product margin is management's measure of the profitability of its annuity, health and life segments' performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs.

(c)

Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our federal home loan bank ("FHLB") investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investments income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.

FINANCIAL SUMMARY (continued)
Management vs. GAAP Measures
(Dollars in millions, except per share data)
(Unaudited)

Shareholders' equity, excluding accumulated other comprehensive income (loss), and book value per share, excluding accumulated other comprehensive income (loss), are non-GAAP measures that are utilized by management to view the business without the effect of accumulated other comprehensive income (loss) which is primarily attributable to fluctuations in interest rates associated with fixed maturities, available for sale. Management views the business in this manner because the Company has the ability and generally, the intent, to hold investments to maturity and meaningful trends can be more easily identified without the fluctuations. In addition, shareholders' equity excludes net operating loss carryforwards in our non-GAAP return on equity measures as such assets are not discounted and, accordingly, will not provide a return to shareholders until after it is realized as a reduction to taxes that would otherwise be paid. Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns.

___________________________________________________________________________________________________


Quarter ended


June 30,


2025


2024

Trailing four quarters:




Net Income

$ 305.5


$ 432.2

Net operating income (a non-GAAP financial measure)

425.8


407.3

Net operating income, excluding significant items

401.7


364.0





Average of each of the trailing four quarters average:




Shareholders' equity

$ 2,558.5


$ 2,171.4

Accumulated other comprehensive loss

1,271.2


1,653.2

Shareholders' equity, excluding accumulated other comprehensive loss

3,829.7


3,824.6





Net operating loss carryforwards

(232.4)


(176.2)

Shareholders' equity, excluding accumulated other comprehensive loss and net operating loss
carryforwards

$ 3,597.3


$ 3,648.4





Ratios:




Return on equity

11.9%


19.9%

Operating return on equity (a non-GAAP financial measure) (5)

11.8%


11.2%

Operating return on equity, excluding significant items (a non-GAAP financial measure) (5)

11.2%


10.0%

Shareholders' equity

$ 2,522.7


$ 2,428.9

Accumulated other comprehensive loss

1,252.7


1,464.3

Shareholders' equity, excluding accumulated other comprehensive loss

3,775.4


3,893.2





Basic shares outstanding

97,319,000


106,513,566

Diluted shares outstanding

99,221,445


108,140,009





Book value per share

$ 25.92


$ 22.80





Book value per diluted share

$ 25.42


$ 22.46

Accumulated other comprehensive loss per diluted share

12.63


13.54

Book value per diluted share, excluding accumulated other comprehensive loss (a non-GAAP financial
measure) (2)

$ 38.05


$ 36.00

Non-Operating Items
Net investment losses in 2Q25 were $21.8 million, including the unfavorable change in the allowance for credit losses of $1.0million. Net investment losses in 2Q24 were $21.9 million, including the favorable change in the allowance for credit losses of $4.1 million.

During 2Q25 and 2Q24, we recognized an increase in earnings of $3.4 million and $4.7 million, respectively, due to the net change in market value of investments.

In 2Q24, we recognized an increase in earnings of $3.5 million for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability. We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change.

During 2Q25 and 2Q24, we recognized an increase in earnings of $25.2 million and $16.8 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and market risk benefits. In addition, certain 4Q24 and 1Q25 amounts were revised to conform to the current period's presentation for the correction of an error that is immaterial to the reported periods. The revision impacted net income, shareholders' equity, and the related metrics of book value per common share, debt-to-capital ratio, and net income � trailing four quarters for those periods.

Other non-operating items in 2Q25 included $3.2 million of expense related to TechMod, a three-year project to modernize certain elements of our technology. In addition, other non-operating items included a reduction in the allowance for credit losses on reinsurance of $2.0 million.

INVESTMENT PORTFOLIO
(Dollars in millions)

Fixed maturities, available for sale, at amortized cost by asset class as of June30, 2025 are as follows:


Investment
grade


Below
investment
grade


Total

Corporate securities

13,380.8


$ 678.1


$ 14,058.9

United States Treasury securities and obligations of the United States government and
agencies

217.9



217.9

States and political subdivisions

3,318.7


23.6


3,342.3

Foreign governments

113.6



113.6

Asset-backed securities

1,497.2


95.8


1,593.0

Agency residential mortgage-backed securities

910.7



910.7

Non-agency residential mortgage-backed securities

1,282.0


326.0

(a)

1,608.0

Collateralized loan obligations

1,091.7



1,091.7

Commercial mortgage-backed securities

2,158.9


133.8


2,292.7

Total

$ 23,971.5


$ 1,257.3


$ 25,228.8

____________________

()

Certain structured securities rated below investment grade by Nationally Recognized Statistical Rating Organizations may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the National Association of Insurance Commissioners (NAIC).

As of June 30, 2025, the fair value of CNO's available for sale fixed maturity portfolio was $23,047.0 million compared with an amortized cost of $25,228.8 million. Net unrealized losses were comprised of gross unrealized gains of $197.1 million and gross unrealized losses of $2,339.8 million as of June 30, 2025. The allowance for credit losses was $39.1 million at June30, 2025.

Statutory (based on non-GAAP measures) and GAAP Capital Information
The consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries was estimated at 378% at June30, 2025, reflecting estimated 2Q25 statutory operating earnings of $22.0 million and the payment of insurance company dividends (net of capital contributions) to the holding company of $35.7 million during 2Q25.

During 2Q25, we repurchased $100.0 million of common stock under our securities repurchase program (including $1.6 million of repurchases settled in 3Q25). We repurchased 2.6 million common shares at an average cost of $38.09 per share. As of June30, 2025, we had 97.3million shares outstanding and had authority to repurchase up to an additional $540.4million of our common stock. During 2Q25, dividends paid on common stock totaled $16.7 million.

Unrestricted cash and investments held by our holding company were $187.1 million at June30, 2025 compared to $372.5 million at December31, 2024.

Book value per common share was $25.92 at June30, 2025 compared to $24.75 at December31, 2024. Book value per diluted share, excluding accumulated other comprehensive income (loss) (2), was $38.05 at June30, 2025 compared to $37.35 at December31, 2024.

The debt-to-capital ratio was 34.6% and 42.2% at June30, 2025 and December31, 2024, respectively. Our debt-to-total capital ratio, excluding accumulated other comprehensive income (loss)(3), was 26.1% and 32.1% at June30, 2025 and December31, 2024, respectively. The reduction in the ratios from December 31, 2024 was primarily due to the repayment of the 2025 Notes in 2Q25.

Return on equity for the trailing four quarters ended June30, 2025 and 2024 was 11.9% and 19.9%, respectively. Operating return on equity, excluding significant items(5), for the trailing four quarters ended June30, 2025 and 2024 was 11.2% and 10.0%, respectively.

In this news release, CNO includes non-GAAP measures to enhance investors' understanding of management's view of the business. The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing a broader perspective. CNO's definitions of non-GAAP measures may differ from other companies' definitions. More detailed information including various GAAP and non-GAAP measurements are located at CNOinc.com in the Investors section under SEC Filings.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This press release may contain forward-looking statements within the meaning of federal securities laws. These prospective statements reflect management's current expectations, but are not guarantees of future performance. Accordingly, please refer to CNO's cautionary statement regarding forward-looking statements, and the business environment in which the Company operates, contained in the Company's Form 10-K for the year ended December31, 2024 and any subsequent Form 10-Q or Form 10-K on file with the Securities and Exchange Commission and on the Company's website at CNOinc.com in the Investors section. CNO specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.

EARNINGS RELEASE CONFERENCE CALL WEBCAST:

The Company will host a conference call to discuss results on July29, 2025 at 11:00 a.m. Eastern Time. During the call, we will be referring to a presentation that will be available at the Investors section of the company's website.

To participate by dial-in, please register at . Upon registering, you will be provided with call details and a registrant ID used to track attendance on the conference call. Reminders will also be sent to registered participants via email.

For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast. The event can be accessed through the Investors section of the company's website: ir.CNOinc.com. Participants should go to the website at least 15 minutes before the event to register and download any necessary audio software.

ABOUT CNO FINANCIAL GROUP

CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities, financial services and workforce benefits solutions through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income and retirement needs with 3.2 million policies and $37.3 billion in total assets. Our3,400 associates, 4,900 exclusive agents and more than 6,000 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS

(Dollars in millions, except per share data)

(unaudited)



Three months ended


Six months ended


June 30,


June 30,


2025


2024


2025


2024

Revenues:








Insurance policy income

$ 651.3


$ 641.5


$ 1,302.0


$ 1,269.9

Net investment income:








General account assets

378.3


351.7


753.4


653.6

Policyholder and other special-purpose portfolios

105.4


57.4


41.8


224.7

Investment gains (losses):








AG˹ٷized investment losses

(21.3)


(26.3)


(25.1)


(36.3)

Other investment gains (losses)

2.9


9.1


(0.1)


26.9

Total investment losses

(18.4)


(17.2)


(25.2)


(9.4)

Fee revenue and other income

34.9


32.8


83.6


83.9

Total revenues

1,151.5


1,066.2


2,155.6


2,222.7

Benefits and expenses:








Insurance policy benefits

658.4


574.4


1,228.4


1,211.0

Liability for future policy benefits remeasurement loss

(12.8)


(30.0)


(25.0)


(36.4)

Change in fair value of market risk benefits

(10.9)


(5.8)


4.4


(24.7)

Interest expense

59.1


64.2


121.1


124.4

Amortization of deferred acquisition costs and present value of future
Ǵھٲ

68.6


61.4


136.0


121.9

Gain on extinguishment of borrowings related to variable interest
entities



(1.5)


Other operating costs and expenses

271.1


251.4


546.4


529.7

Total benefits and expenses

1,033.5


915.6


2,009.8


1,925.9

Income before income taxes

118.0


150.6


145.8


296.8

Income tax expense

26.2


34.3


32.5


68.2

Net income

$ 91.8


$ 116.3


$ 113.3


$ 228.6

Earnings per common share:








Basic:








Weighted average shares outstanding

98,572,000


107,731,000


99,658,000


108,347,000

Net income

$ 0.93


$ 1.08


$ 1.14


$ 2.11

Diluted:








Weighted average shares outstanding

100,386,000


109,258,000


101,728,000


110,052,000

Net income

$ 0.91


$ 1.06


$ 1.11


$ 2.08

NOTES

(1)

Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) gains or losses related to material reinsurance transactions, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation, net of taxes; and (ix) other non-operating items including earnings attributable to variable interest entities, net of taxes ("net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of results of our insurance product lines. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 2. Additional information concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available on CNO's website, CNOinc.com, in the Investors section under SEC Filings.

(2)

Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.

(3)

The calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.

(4)

Measured by new annualized premiums for life and health products, which includes 10% of single premium whole life deposits and 100% of all other premiums (excluding annuities). Sales of third-party products are excluded.

(5)

Operating return on equity and operating return on equity, excluding significant items are calculated as follows: (i) operating return on equity is equal to the trailing four quarters of net operating income(1) divided by average shareholders' equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards, for the trailing four quarters; and (ii) operating return on equity, excluding significant items is equal to the trailing four quarters of net operating income(1), excluding significant items, divided by average shareholders' equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards, for the trailing four quarters.

The following summarizes: (i) net operating income; (ii) significant items; (iii) net operating income, excluding significant items; and (iv) net income (loss) (dollars in millions):









Net operating











Net operating


income,











income,


excluding




Net







excluding


significant




income -



Net operating


Significant


significant


items - trailing


Net


trailing



income


items


items (a)


four quarters


income (loss)


four quarters

3Q23


$ 101.3


$ (16.9)

(b)

$ 84.4


$ 287.7


$ 167.3


$ 278.2

4Q23


133.9


(26.4)

(c)

107.5


312.8


36.3


276.5

1Q24


57.5



57.5


311.7


112.3


389.6

2Q24


114.6



114.6


364.0


116.3


432.2

3Q24


119.2


(21.9)

(d)

97.3


376.9


9.3


274.2

4Q24


138.0


3.1

(e)

141.1


410.5


182.9


420.8

1Q25


81.1


(5.3)

(f)

75.8


428.8


21.5


330.0

2Q25


87.5



87.5


401.7


91.8


305.5














()

See note (6) for additional information.















()

Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals, net of tax expense of $4.8 million.















()

Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $7.5 million.















()

Comprised of $31.2 million of the net favorable impact arising from our comprehensive annual actuarial review and $2.9 million of the unfavorable impact related to a fixed asset impairment, net of tax expense of $6.4 million.















()

Comprised of $3.9 million of the unfavorable impact arising from our comprehensive annual actuarial review, net of tax expense of $0.8 million.















()

Comprised of $6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves, net of tax expense of $1.5 million.

A reconciliation of pre-tax operating earnings (a non-GAAP financial measure) to net income is as follows (dollars in millions):




Trailing four quarters




2Q25


2Q24

Pre-tax operating earnings (a non-GAAP financial measure)

$ 544.3


$ 525.3

Income tax expense

(118.5)


(118.0)

Net operating income

425.8


407.3

Non-operating items:




Net realized investment losses from sales, impairments and change in allowance for credit
losses

(81.2)


(45.2)

Net change in market value of investments recognized in earnings

15.5


16.7

Changes in fair value of embedded derivative liabilities and market risk benefits

(78.9)


65.6

Fair value changes related to the agent deferred compensation plan

3.1


Other

(13.9)


(3.9)

Non-operating loss before taxes

(155.4)


33.2

Income tax benefit on non-operating loss

35.1


(8.3)

Net non-operating loss

(120.3)


24.9

Net income

$ 305.5


$ 432.2

A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows (dollars in millions):




1Q23


2Q23


3Q23


4Q23

Consolidated capital, excluding accumulated other comprehensive









income (loss) and net operating loss carryforwards









(a non-GAAP financial measure)

$ 3,543.8


$ 3,603.0


$ 3,744.2


$ 3,712.8

Net operating loss carryforwards

152.4


126.3


102.6


79.6

Accumulated other comprehensive loss

(1,664.4)


(1,733.5)


(1,956.7)


(1,576.8)

Common shareholders' equity

$ 2,031.8


$ 1,995.8


$ 1,890.1


$ 2,215.6














1Q24


2Q24


3Q24


4Q24

Consolidated capital, excluding accumulated other comprehensive









income (loss) and net operating loss carryforwards









(a non-GAAP financial measure)

$ 3,536.8


$ 3,596.7


$ 3,529.9


$ 3,810.0

Net operating loss carryforwards

311.2


296.5


273.9


76.6

Accumulated other comprehensive loss

(1,480.3)


(1,464.3)


(1,116.0)


(1,371.4)

Common shareholders' equity

$ 2,367.7


$ 2,428.9


$ 2,687.8


$ 2,515.2














1Q25


2Q25





Consolidated capital, excluding accumulated other comprehensive









income (loss) and net operating loss carryforwards









(a non-GAAP financial measure)

$ 3,498.9


$ 3,504.3





Net operating loss carryforwards

295.3


271.1





Accumulated other comprehensive loss

(1,239.1)


(1,252.7)





Common shareholders' equity

$ 2,555.1


$ 2,522.7





A reconciliation of consolidated capital, excluding accumulated other comprehensive loss and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows (dollars in millions):



Trailing four quarter average



2Q25


2Q24

Consolidated capital, excluding accumulated other comprehensive





income (loss) and net operating loss carryforwards





(a non-GAAP financial measure)

$ 3,597.3


$ 3,648.4

Net operating loss carryforwards

232.4


176.2

Accumulated other comprehensive loss

(1,271.2)


(1,653.2)

Common shareholders' equity

$ 2,558.5


$ 2,171.4

(6)

The tables below summarize the financial impact of significant items on our net operating income for the three months ended March 31, 2025 and the quarters during the year ended December 31, 2024 that had significant items impacting our net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results (dollars in millions, except per share data).



Three months ended



March 31, 2025



Actual
results


Significant
items


Excluding
significant

items

Insurance product margin







Annuity margin


$ 54.5


$ �


$ 54.5

Health margin


126.2



126.2

Life margin


68.2


(6.8)

(a)

61.4

Total insurance product margin


248.9


(6.8)


242.1

Allocated expenses


(161.2)



(161.2)

Income from insurance products


87.7


(6.8)


80.9

Fee income


(0.8)



(0.8)

Investment income not allocated to product lines


38.0



38.0

Expenses not allocated to product lines


(20.3)



(20.3)

Operating earnings before taxes


104.6


(6.8)


97.8

Income tax (expense) benefit on operating income


(23.5)


1.5


(22.0)

Net operating income


$ 81.1


$ (5.3)


$ 75.8








Net operating income per diluted share


$ 0.79


$ (0.05)


$ 0.74

___________

()

Comprised of $6.8 million of the favorable impact of an out-of-period adjustment, which decreased reserves.



Three months ended



December 31, 2024



Actual
results


Significant
items


Excluding
significant

items

Insurance product margin







Annuity margin


$ 55.0


$ �


$ 55.0

Health margin


130.1


3.9

(a)

134.0

Life margin


68.0



68.0

Total insurance product margin


253.1


3.9


257.0

Allocated expenses


(146.1)



(146.1)

Income from insurance products


107.0


3.9


110.9

Fee income


20.6



20.6

Investment income not allocated to product lines


65.3



65.3

Expenses not allocated to product lines


(19.0)



(19.0)

Operating earnings before taxes


173.9


3.9


177.8

Income tax (expense) benefit on operating income


(35.9)


(0.8)


(36.7)

Net operating income


$ 138.0


$ 3.1


$ 141.1








Net operating income per diluted share


$ 1.31


$ 0.03


$ 1.34

___________

()

Comprised of $3.9 million of the unfavorable impact arising from our comprehensive annual actuarial review.



Three months ended



September 30, 2024



Actual
results


Significant
items


Excluding
significant

items

Insurance product margin







Annuity margin


$ 91.1


$ (36.2)

(a)

$ 54.9

Health margin


127.8


4.3

(a)

132.1

Life margin


63.3


0.7

(a)

64.0

Total insurance product margin


282.2


(31.2)


251.0

Allocated expenses


(153.0)



(153.0)

Income from insurance products


129.2


(31.2)


98.0

Fee income


(2.7)



(2.7)

Investment income not allocated to product lines


45.5



45.5

Expenses not allocated to product lines


(18.5)


2.9

(b)

(15.6)

Operating earnings before taxes


153.5


(28.3)


125.2

Income tax (expense) benefit on operating income


(34.3)


6.4


(27.9)

Net operating income


$ 119.2


$ (21.9)


$ 97.3








Net operating income per diluted share


$ 1.11


$ (0.19)


$ 0.92

___________

()

Comprised of $31.2 million of net favorable impact arising from our comprehensive annual actuarial review.

()

Comprised of $2.9 million of the unfavorable impact related to a fixed asset impairment.

Cision View original content to download multimedia:

SOURCE CNO Financial Group

FAQ

What was CNO Financial Group's earnings per share in Q2 2025?

CNO reported net income of $0.91 per diluted share and net operating income of $0.87 per diluted share in Q2 2025.

How much capital did CNO return to shareholders in Q2 2025?

CNO returned $116.7 million to shareholders, including $100.0 million in share repurchases and $16.7 million in dividends.

What was CNO's book value per share in Q2 2025?

CNO's book value per share was $25.92, while book value per diluted share excluding accumulated other comprehensive loss was $38.05, up 6%.

How did CNO's sales performance compare to the previous year?

CNO showed strong sales growth with total new annualized premiums up 17%, Life NAP up 22%, Health NAP up 11%, and annuity collected premiums up 19% year-over-year.

What was CNO's operating return on equity in Q2 2025?

CNO achieved an operating ROE of 11.8% and remains on track to meet its 2025-2027 return on equity targets.
Cno Finl Group Inc

NYSE:CNO

CNO Rankings

CNO Latest News

CNO Latest SEC Filings

CNO Stock Data

3.75B
96.80M
2.08%
97.57%
1.82%
Insurance - Life
Accident & Health Insurance
United States
CARMEL